A bipartisan bill aimed at helping terminally ill patients gain access to experimental medicines would leave intact the controversial role of the Food and Drug Administration, a notion that will likely upset backers of the so-called right-to-try movement.

The draft legislation, which is being developed with help from the FDA, also includes a provision that seeks to reassure anxious drug makers about making their treatments available, but to what extent this move makes the effort easier to forge a compromise is uncertain.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Ah, an interesting point of view – “we don’t believe the government should have a role in that decision-making process once a drug is determined to be safe enough to give to people in human trials,” said Starlee Coleman, a spokeswoman for the Goldwater Institute” – but there is a true difference between safe enough for trials and ‘safe and effective.’
    Trials do surprise, don’t they? I will demure from providing examples.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy